{"ClinicalTrials":[{"allLocations":"United States:Newark,Recruiting;","authority":"United States: Institutional Review Board","briefTitle":"Safety of Platelet Transfusion in Patients on Antiplatelet Therapy With Traumatic Head Injury","criteria":"\n        Inclusion Criteria:\n\n          -  18 years or older\n\n          -  Evidence of intracranial hemorrhage (bleeding in the brain) by CT scan related to\n             traumatic injury\n\n          -  Receiving antiplatelet therapy such as aspirin, thienopyridine (ticlopidine,\n             clopidogrel, or prasugrel)\n\n          -  Platelet count greater than or equal to 100,000\n\n        Exclusion Criteria:\n\n          -  Glasgow Coma Scale (GCS) less than 6\n\n          -  Hemorrhage requiring emergent surgery\n\n          -  Lack of permission from treating physician and/or consultant\n\n          -  Secondary ICH related to aneurysm or arteriovenous malformation\n\n          -  Use of oral anticoagulants\n\n          -  Decreased platelets (thrombocytopenia)\n\n          -  Patients requiring massive transfusion protocol\n\n          -  Life expectancy less than 3 months\n\n          -  Confirmed acute heart attack\n\n          -  Hepatitis and liver cirrhosis\n\n          -  Kidney failure\n\n          -  Participation in another treatment study within the preceding 30 days\n      ","endDate":"April 2013","gender":"Both","maxAge":"0","minAge":"18","officialAffiliation":"NA","officialLastName":"Debra R. Marco, RN, BSN, CCRC","officialRole":"Principal Investigator","officialTitle":"The Safety and Efficacy of Platelet Transfusion in Patients Receiving Antiplatelet Therapy That Sustain Traumatic Intracranial Hemorrhage","phase":"Phase 4","data":"March 28, 2013","sponsors":"Christiana Care Health Services","stDate":"June 2012","status":"Recruiting","studyDesign":"Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment","studyType":"Interventional","summary":"\n      The objective of this study is to determine if the administration of platelets will improve\n      outcome in patients with ICH who are being treated with either aspirin, a thienopyridine\n      (ticlodipine, clopidogrel, prasugrel) or a combination of both. The study has four specific\n      aims:\n\n        1. To determine what affect platelet administration will have on bleeding in the brain.\n\n        2. To determine what affect platelet administration will have on brain function.  Several\n           assessments to test the functioning of the brain will be performed at enrollment and\n           throughout the study.  Comparing the results of these assessments between the\n           experimental and control groups should allow us to determine if platelet administration\n           improves outcomes in patients with bleeding in the brain exposed to antiplatelet\n           therapy.\n\n        3. An important risk of reversing antiplatelet therapy is exposing the patient to the very\n           complications this therapy was designed to prevent.  Therefore, tracking complications\n           will be a very important part of this study.  The investigators will compare the rates\n           of death, heart attack, stroke and clots in the veins between groups.\n\n        4. Some patients (10-40%) have limited responsiveness to antiplatelet therapy.  While\n           platelet responsiveness, as measured by a special platelet blood test, will not affect\n           enrollment, the investigators feel it will be important to measure.\n    ","tags":"traumatic head injury intracranial hemorrhage platelets anti-platelet therapy plavix asprin ","trialId":"NCT01810276"},{"allLocations":"United States:Newark,Recruiting;","authority":"United States: Institutional Review Board","briefTitle":"Safety of Platelet Transfusion in Patients on Antiplatelet Therapy With Traumatic Head Injury","criteria":"\n        Inclusion Criteria:\n\n          -  18 years or older\n\n          -  Evidence of intracranial hemorrhage (bleeding in the brain) by CT scan related to\n             traumatic injury\n\n          -  Receiving antiplatelet therapy such as aspirin, thienopyridine (ticlopidine,\n             clopidogrel, or prasugrel)\n\n          -  Platelet count greater than or equal to 100,000\n\n        Exclusion Criteria:\n\n          -  Glasgow Coma Scale (GCS) less than 6\n\n          -  Hemorrhage requiring emergent surgery\n\n          -  Lack of permission from treating physician and/or consultant\n\n          -  Secondary ICH related to aneurysm or arteriovenous malformation\n\n          -  Use of oral anticoagulants\n\n          -  Decreased platelets (thrombocytopenia)\n\n          -  Patients requiring massive transfusion protocol\n\n          -  Life expectancy less than 3 months\n\n          -  Confirmed acute heart attack\n\n          -  Hepatitis and liver cirrhosis\n\n          -  Kidney failure\n\n          -  Participation in another treatment study within the preceding 30 days\n      ","endDate":"April 2013","gender":"Both","maxAge":"0","minAge":"18","officialAffiliation":"NA","officialLastName":"Debra R. Marco, RN, BSN, CCRC","officialRole":"Principal Investigator","officialTitle":"The Safety and Efficacy of Platelet Transfusion in Patients Receiving Antiplatelet Therapy That Sustain Traumatic Intracranial Hemorrhage","phase":"Phase 4","data":"October 28, 2013","sponsors":"Christiana Care Health Services","stDate":"June 2012","status":"In Progress","studyDesign":"Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment","studyType":"Interventional","summary":"\n      The objective of this study is to determine if the administration of platelets will improve\n      outcome in patients with ICH who are being treated with either aspirin, a thienopyridine\n      (ticlodipine, clopidogrel, prasugrel) or a combination of both. The study has four specific\n      aims:\n\n        1. To determine what affect platelet administration will have on bleeding in the brain.\n\n        2. To determine what affect platelet administration will have on brain function.  Several\n           assessments to test the functioning of the brain will be performed at enrollment and\n           throughout the study.  Comparing the results of these assessments between the\n           experimental and control groups should allow us to determine if platelet administration\n           improves outcomes in patients with bleeding in the brain exposed to antiplatelet\n           therapy.\n\n        3. An important risk of reversing antiplatelet therapy is exposing the patient to the very\n           complications this therapy was designed to prevent.  Therefore, tracking complications\n           will be a very important part of this study.  The investigators will compare the rates\n           of death, heart attack, stroke and clots in the veins between groups.\n\n        4. Some patients (10-40%) have limited responsiveness to antiplatelet therapy.  While\n           platelet responsiveness, as measured by a special platelet blood test, will not affect\n           enrollment, the investigators feel it will be important to measure.\n    ","tags":"traumatic head injury intracranial hemorrhage platelets anti-platelet therapy plavix asprin ","trialId":"NCT01810276"},{"allLocations":"United States:Newark,Recruiting;","authority":"United States: Institutional Review Board","briefTitle":"Safety of Platelet Transfusion in Patients on Antiplatelet Therapy With Traumatic Head Injury","criteria":"\n        Inclusion Criteria:\n\n          -  18 years or older\n\n          -  Evidence of intracranial hemorrhage (bleeding in the brain) by CT scan related to\n             traumatic injury\n\n          -  Receiving antiplatelet therapy such as aspirin, thienopyridine (ticlopidine,\n             clopidogrel, or prasugrel)\n\n          -  Platelet count greater than or equal to 100,000\n\n        Exclusion Criteria:\n\n          -  Glasgow Coma Scale (GCS) less than 6\n\n          -  Hemorrhage requiring emergent surgery\n\n          -  Lack of permission from treating physician and/or consultant\n\n          -  Secondary ICH related to aneurysm or arteriovenous malformation\n\n          -  Use of oral anticoagulants\n\n          -  Decreased platelets (thrombocytopenia)\n\n          -  Patients requiring massive transfusion protocol\n\n          -  Life expectancy less than 3 months\n\n          -  Confirmed acute heart attack\n\n          -  Hepatitis and liver cirrhosis\n\n          -  Kidney failure\n\n          -  Participation in another treatment study within the preceding 30 days\n      ","endDate":"April 2013","gender":"Both","maxAge":"0","minAge":"18","officialAffiliation":"NA","officialLastName":"Debra R. Marco, RN, BSN, CCRC","officialRole":"Principal Investigator","officialTitle":"The Safety and Efficacy of Platelet Transfusion in Patients Receiving Antiplatelet Therapy That Sustain Traumatic Intracranial Hemorrhage","phase":"Phase 4","data":"December 28, 2013","sponsors":"Christiana Care Health Services","stDate":"June 2012","status":"Completed","studyDesign":"Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment","studyType":"Interventional","summary":"\n      The objective of this study is to determine if the administration of platelets will improve\n      outcome in patients with ICH who are being treated with either aspirin, a thienopyridine\n      (ticlodipine, clopidogrel, prasugrel) or a combination of both. The study has four specific\n      aims:\n\n        1. To determine what affect platelet administration will have on bleeding in the brain.\n\n        2. To determine what affect platelet administration will have on brain function.  Several\n           assessments to test the functioning of the brain will be performed at enrollment and\n           throughout the study.  Comparing the results of these assessments between the\n           experimental and control groups should allow us to determine if platelet administration\n           improves outcomes in patients with bleeding in the brain exposed to antiplatelet\n           therapy.\n\n        3. An important risk of reversing antiplatelet therapy is exposing the patient to the very\n           complications this therapy was designed to prevent.  Therefore, tracking complications\n           will be a very important part of this study.  The investigators will compare the rates\n           of death, heart attack, stroke and clots in the veins between groups.\n\n        4. Some patients (10-40%) have limited responsiveness to antiplatelet therapy.  While\n           platelet responsiveness, as measured by a special platelet blood test, will not affect\n           enrollment, the investigators feel it will be important to measure.\n    ","tags":"traumatic head injury intracranial hemorrhage platelets anti-platelet therapy plavix asprin ","trialId":"NCT01810276"}]}